[go: up one dir, main page]

WO2006117666A3 - Dosage forms, pharmaceutical compositions and methods for sub-tenon delivery - Google Patents

Dosage forms, pharmaceutical compositions and methods for sub-tenon delivery Download PDF

Info

Publication number
WO2006117666A3
WO2006117666A3 PCT/IB2006/001158 IB2006001158W WO2006117666A3 WO 2006117666 A3 WO2006117666 A3 WO 2006117666A3 IB 2006001158 W IB2006001158 W IB 2006001158W WO 2006117666 A3 WO2006117666 A3 WO 2006117666A3
Authority
WO
WIPO (PCT)
Prior art keywords
dosage forms
sub
pharmaceutical compositions
methods
tenon
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2006/001158
Other languages
French (fr)
Other versions
WO2006117666A2 (en
Inventor
Channing Rodney Beals
Wesley Warren Day
Deborah Anne Khalil
Karen Jean Klamerus
Susan Renee Raber
Baldo Scassellati-Sorzolini
Samuel Hyman Zwillich
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Corp Belgium
Pfizer Corp SRL
Original Assignee
Pfizer Corp Belgium
Pfizer Corp SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Corp Belgium, Pfizer Corp SRL filed Critical Pfizer Corp Belgium
Publication of WO2006117666A2 publication Critical patent/WO2006117666A2/en
Publication of WO2006117666A3 publication Critical patent/WO2006117666A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicinal Preparation (AREA)

Abstract

The invention provides dosage forms of compounds of Formula (I), (II) or (III), or pharmaceutically acceptable salts or solvates thereof, and pharmaceutical compositions thereof, for sub-Tenon administration to the posterior segment of the eye proximate the macula in a mammal with age-related macular degeneration. The invention further provides methods of treating age-related macular degeneration in a mammal by administering these dosage forms.
PCT/IB2006/001158 2005-04-29 2006-04-18 Dosage forms, pharmaceutical compositions and methods for sub-tenon delivery Ceased WO2006117666A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US67606005P 2005-04-29 2005-04-29
US60/676,060 2005-04-29

Publications (2)

Publication Number Publication Date
WO2006117666A2 WO2006117666A2 (en) 2006-11-09
WO2006117666A3 true WO2006117666A3 (en) 2007-01-18

Family

ID=37055940

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2006/001158 Ceased WO2006117666A2 (en) 2005-04-29 2006-04-18 Dosage forms, pharmaceutical compositions and methods for sub-tenon delivery

Country Status (4)

Country Link
JP (1) JP2006306877A (en)
AR (1) AR054442A1 (en)
TW (1) TW200719893A (en)
WO (1) WO2006117666A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101370505B (en) * 2005-11-29 2012-03-21 史密丝克莱恩比彻姆公司 Treatment of neovascular eye diseases such as macular degeneration, angioid striae, uveitis, and macular edema
JO3387B1 (en) 2011-12-16 2019-03-13 Glaxosmithkline Llc Derivatives of betulin
SG10201704467SA (en) * 2012-12-14 2017-06-29 Glaxosmithkline Llc Pharmaceutical compositions
CN106999425A (en) 2014-09-26 2017-08-01 葛兰素史克知识产权第二有限公司 Depot drug product composition
JP2018065920A (en) * 2016-10-19 2018-04-26 中越パルプ工業株式会社 Cellulose nanofiber and method for producing cellulose nanofiber
CN116251186B (en) * 2021-12-09 2025-04-25 成都瑞沐生物医药科技有限公司 A tyrosine kinase inhibitor ophthalmic preparation and its preparation method and use

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6531491B1 (en) * 1999-07-02 2003-03-11 Agouron Pharamaceuticals, Inc. Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
WO2003106462A1 (en) * 2002-06-14 2003-12-24 Pfizer Inc. Benzofused heteroaryl amide derivatives of thienopyridines useful as therapeutic agents, pharmaceutical compositions including the same, and methods for their use
WO2004056806A1 (en) * 2002-12-19 2004-07-08 Pfizer Inc. 2-(1h-indazol-6-ylamino)-benzamide compounds as protein kinases inhibitors useful for the treatment of ophtalmic diseases
WO2006043172A1 (en) * 2004-10-19 2006-04-27 Pfizer Inc. Pharmaceutical compositions and methods for sub-tenon delivery

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6531491B1 (en) * 1999-07-02 2003-03-11 Agouron Pharamaceuticals, Inc. Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
WO2003106462A1 (en) * 2002-06-14 2003-12-24 Pfizer Inc. Benzofused heteroaryl amide derivatives of thienopyridines useful as therapeutic agents, pharmaceutical compositions including the same, and methods for their use
WO2004056806A1 (en) * 2002-12-19 2004-07-08 Pfizer Inc. 2-(1h-indazol-6-ylamino)-benzamide compounds as protein kinases inhibitors useful for the treatment of ophtalmic diseases
WO2006043172A1 (en) * 2004-10-19 2006-04-27 Pfizer Inc. Pharmaceutical compositions and methods for sub-tenon delivery

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
GALE D C ET AL: "Ocular pharmacokinetics in single compound and cassette dose studies following sub-Tenon administration in Dutch-belted rabbits", IOVS, vol. 46, no. Suppl. S, 2005, & ANNUAL MEETING OF THE ASSOCIATION-FOR-RESEARCH-IN-VISION-AND-OPHTHALM OLOGY; FT LAUDERDALE, FL, USA; MAY 01 -05, 2005, pages 5381, XP009073501, ISSN: 0146-0404 *

Also Published As

Publication number Publication date
JP2006306877A (en) 2006-11-09
TW200719893A (en) 2007-06-01
AR054442A1 (en) 2007-06-27
WO2006117666A2 (en) 2006-11-09

Similar Documents

Publication Publication Date Title
WO2009035673A8 (en) Compositions and methods for treating macular degeneration
MX344036B (en) Compositions comprising azelastine and methods of use thereof.
MX354184B (en) Alkoxy compounds for disease treatment.
MX351152B (en) Compstatin and analogs thereof for eye disorders.
PH12015501208A1 (en) Amine derivative compounds for treating ophthalmic diseases and disorders
EA200870423A1 (en) DERIVATIVES OF TRIAZOLPYRAZINES APPLICABLE AS ANTI-CANCER AGENTS
BRPI0811142A8 (en) prevention and treatment of eye conditions associated with supplements
WO2005117954A3 (en) Compositions and methods for treatment of neovascular diseases
WO2010048332A3 (en) Compounds for treating ophthalmic diseases and disorders
WO2011127333A3 (en) Compounds for treating disease, for administering, and for pharmaceutical compositions
MX2010000351A (en) Alkynyl phenyl derivative compounds for treating ophthalmic diseases and disorders.
HK1198869A1 (en) Combination treatments for hepatitis c
PH12022551226A1 (en) Pyrrolotriazine compounds acting as mnk inhibitor
WO2010005580A3 (en) Methods and compositions of small molecule modulators of hepatocyte growth factor (scatter factor) activity
WO2007046083A3 (en) Compositions for treatment of eye diseases
WO2008020032A8 (en) Use of 2,5-dihydroxybenzene derivatives for the treatment of ocular diseases
WO2006138608A3 (en) Pharmaceutical compositions and use thereof
WO2008070010A3 (en) Hydroxylamine derivatives for the treatment of stroke
TW200626158A (en) Naphthaline derivatives
AR064543A1 (en) USE OF DIANHYDROHEXITE MONONITRATE DERIVATIVES AS AGENTS FOR THE TREATMENT OF INTESTINAL DISORDERS
WO2007057221A3 (en) Pharmaceutical compositions for the treatment of inflammatory and obstructive airways diseases
WO2008048675A3 (en) Treatment for age-related macular degeneration and other diseases of the eye
WO2008008882A3 (en) Glucocorticoid receptor modulator and methods of use
WO2006117666A3 (en) Dosage forms, pharmaceutical compositions and methods for sub-tenon delivery
EA200900582A1 (en) PHARMACEUTICAL COMPOSITIONS FOR PREVENTION AND TREATMENT OF EYE PATHOLOGIES

Legal Events

Date Code Title Description
DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

NENP Non-entry into the national phase

Ref country code: RU

WWW Wipo information: withdrawn in national office

Country of ref document: RU

122 Ep: pct application non-entry in european phase

Ref document number: 06755857

Country of ref document: EP

Kind code of ref document: A2